Trial · NCT00275067
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
NCT00275067, Phase 1, Phase 2, Unknown, Northwestern University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery. Trials, record NCT00275067. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00275067
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
- NCT number
- NCT00275067
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Northwestern University
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- arsenic trioxide, temozolomide, radiation therapy
- First posted
- 2006-01-11
- Last updated
- 2020-02-25
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum tolerated dose of arsenic trioxide and temozolomide in combination with radiotherapy | Toxicity evaluated prior to each treatment cycle | Escalating doses of study drug until dose limiting toxicities are observed. |
| Primary | Collect data on the toxicity of arsenic and temozolomide during radiation therapy | Toxicity evaluated prior to each treatment cycle | Toxicity of this drug combination during radiation therapy will be assessed. |
| Primary | Assess serum biomarkers and correlate with tumor tissue | At baseline, during radiation therapy, and prior to each cycle of chemotherapy | Blood will be drawn at baseline, during radiation therapy, and prior to each cycle of chemotherapy to assess serum biomarkers and correlate with tumor tissue. |
| Secondary | Determine progression free survival at 6 and 12 months | At 6 and 12 months after beginning chemotherapy | Patients will undergo an MRI and neurological evaluation every 6 months while on chemotherapy. |
| Secondary | Determine time to disease progression | At 6 and 12 months after beginning chemotherapy | Disease status will be assessed by MRI and neurological examination every 6 months until disease progression. |
| Secondary | To determine overall survival | Every 6 months while on treatment | Survival status will be evaluated every 6 months while on treatment. |
| Secondary | To determine radiographic response to study regimen | Every 6 months while on treatment | Radiographic response will be assessed by MRI every 6 months while on treatment |
| Secondary | To collect safety data during the radiation therapy phase | Weekly during radiation therapy | EKG's will be done once per week and labs twice per week during radiation therapy phase to evaluate safety data. |
| Secondary | To evaluate a potential surrogate marker for outcomes | At baseline, before and after radiation therapy, and every 2 cycles during chemotherapy | Blood will be drawn to analyze methylation patterns as a surrogate marker for outcomes at baseline, before and after radiation therapy, and every 2 cycles during chemotherapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00275067
GET https://conductscience.org/api/trials/v1/NCT00275067/registered